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immobilised patient on renal replacement
therapy reflects the extent of bone loss – a case
report
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Background: Demineralisation and bone density loss during immobilisation are known phenomena. However
information concerning the extent of calcium loss during immobilisation remains inconsistent within literature.
This may explain why treatment of bone loss and prevention of further demineralisation is often initiated only
when spontaneous bone fracture occurred.
Continuous renal replacement therapy is commonly utilised in critically ill patients with acute kidney injury
requiring RRT. Regional anticoagulation with citrate for CRRT is well-established within the intensive care setting.
Due to calcium free dialysate, calcium is eliminated directly as well as indirectly via citrate binding necessitating
calcium substitution. In anuric patients declining calcium requirements over time reflect bone calcium liberation
secondary to immobilisation. The difference between the expected and actual need for calcium infusion corresponds
to calcium release from bone which is particularly impressive in patients exposed to long-term immobilisation and
CRRT. We report a dialysis period in excess of 250 days with continuous renal replacement therapy and anticoagulation
with citrate.
Case presentation: We present a 30-year old male with prolonged multisystem organ failure after bilateral lung
transplantation, in whom during a period of 254 days the cumulative difference between expected and actual need for
calcium infusion was 14.25 mol, representing an estimated calcium loss of about 571 g. Comparison of computed
tomographic imaging of the lower thoracic vertebrae over this period depicts a radiographically discernible decrease
in bone density from 238 to 52 Hounsfield Units. The first spontaneous fracture occurred after 6 months of
immobilisation. Despite subsequent treatment with bisphosphonates and androgen therapy resulting in an increase in
bone density to 90 HU a further fracture occurred.
Conclusion: In immobilised patients receiving CRRT and anticoagulation with citrate, decreasing need for calcium
substitution reflects the degree of bone demineralisation corresponding with radiographic assessment of declining
bone mineral density. Such a declining need for calcium substitution could be useful in clinical practice highlighting
relevant bone loss which results in spontaneous fractures in immobilised critically ill patients.
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Although demineralisation and bone loss secondary to
long-term immobilisation in critically ill patients are
known phenomena, in clinical practice bone loss is gen-
erally considered less important with respect to disease
severity and the context of intensive care being respon-
sible for immobilisation. Immobilisation results in bone
loss [1] and may result in spontaneous fractures [2].
However, information about the degree of bone loss and
the magnitude of corresponding calcium loss is some-
what inconsistent within literature, being quantified by
two different approaches: 1) renal calcium loss calcu-
lated as the difference between increased urinary and
faecal calcium excretion and net absorption [3,4], with
the assumption that this difference corresponds to bone
demineralisation, 2) comparison of bone mineral density
through x-ray absorptiometry (DXA) scans – the more
commonly utilised method [4] - with a calculated total
body calcium loss during immobilisation in healthy volun-
teers of ~0.7% per month [4].
Using CVVHD for continuous renal replacement
therapy (multifiltrate CiCa, Fresenius, Bad Homburg)
with regional citrate anticoagulation the concentration
of ionised calcium in the extracorporeal circuit is reduced
to 0.25-0.35 mmol/l through chelation with citrate. Cal-
cium is effectively eliminated during dialysis. To restore a
physiological calcium level (normal range 2.2-2.6 mmol/l),
calcium has to be added prior to return of the dialysed
blood to the patient’s circulation. In anuric patients with
unchanged dietary calcium intake or intestinal loss, a de-
clining need for calcium infusion to restore physiological
serum calcium level corresponds to increasing bone cal-
cium release secondary to immobilisation [2].
The current case analysis had two aims: 1) to assess
calcium loss following immobilisation though declining
calcium infusion requirements during CRRT with regional
citrate anticoagulation, and 2) to verify this new method
for estimation of calcium and bone loss during immobil-
isation by correlation with radiographically depicted bone
demineralisation.
Case presentation
A 30-year old male patient with cystic fibrosis under-
went bilateral lung transplantation. Postoperative persist-
ent pulmonary infection and multisystem organ failure
ensued, with CVVHD initiated for acute renal failure.
Graft failure of the left lung resulted in unilateral re-
transplantation. The patient remained immobile due to
persistent infection and multiple organ dysfunctions.
Spontaneous fracture of the left tibia occurred after
6 months of immobility. The following weeks saw a pro-
gressive respiratory and clinical deterioration resulting in
the patient’s death.Clinical course and study results
Total CVVHD duration was 254 days, with a mean dia-
lysis period of 22.5 hours per day. Applied dialysis dose
averaged at 37.8 ml/kg/h. For anticoagulation a mean of
4.0 mmol (3.4 to 4.3) citrate per litre blood was given,
permitting a mean circuit lifespan of 64.4 hours. Mean
calcium substitution was 0.5 mmol/l dialysate. Initial
requirements of 1.7 mmol/l decreased after 27 days as
shown in Figure 1. The lowest level of calcium substitu-
tion was 0.2 mmol/l. The calculated gap between actual
calcium substitution and the theoretical need resulted in
an estimated total calcium loss of 14.25 mol (about 571 g).
Bisphosphonate therapy was initiated when spontaneous
fracture occurred, and testosterone substituted after meas-
urement of total testosterone level (0.76 ng/ml - normal
range: 2.49-8.36 ng/ml).
At admission our patient showed normal renal function
(eGFR (CKD-EPI) 143 ml/min, calculated GFR based on
cystatin C 105 ml/min). Serum calcium measured within
the normal range (2.5 mmol/l). Although iPTH was not
determined at admission, pre-existing elevated iPTH
levels had been noted. Parathyroid hormone levels were
measured at day 152, 181, and 222 of CVVHD with values
between 237–424 pg/ml (normal range: 10–50 pg/ml,
Table 1). Serum calcitonin, vitamin A, and thyroid hor-
mone levels remained within physiological parameters.
Mean serum phosphate was 3.2 ± 0.84 mg/dl (1.03 ±
0.26 mmol/l). Initial vitamin D levels lay within the target
range of >30 ng/ml and decreased over time despite sub-
stitution (Table 1).
Computed tomographic imaging was performed at
several points during the hospital stay. Bone density of
the lower thoracic vertebrae was used as the basis for
radiological comparison. Semi-quantitative assessment
of bone demineralisation by radiodensity was described
in Hounsfield Units (HU). Three years prior to admis-
sion thoracolumbar vertebrae showed a mineralisation
with age-adjusted configuration within normal limits. At
242 HU bone mineral density (BMD) was within physio-
logical limits (Figure 2). Although little change in BMD
was seen at admission, a decrease to 52 HU was noted at
4.5 months after admission (day 95 of CVVHD). A parallel
reduction in vertebral body height was clearly visible. Im-
aging 9 months after admission showed vertebral height
remained unchanged, with an increase in BMD (90 HU)
permitting differentiation between the trailing edge of the
vertebral bodies and the spinal canal.
Bone loss following immobilisation in literature
Published data concerning calcium loss secondary to
bone demineralisation following immobilisation remain
sparse and somewhat inconsistent within literature. Im-
mobilisation trials amongst volunteers and astronauts
have reported a calcium loss of 200-300 mg per day [5],
Figure 1 Daily mean need for calcium substitution per litre dialysate. Initial CVVHD required a calcium substitution of 1.7 mmol/l dialysate
to maintain a serum ionised calcium level within physiological limits (dashed line). From day 27 of CVVHD requirement rapidly decreased. The
lowest mean daily calcium substitution was 0.2 mmol calcium/l dialysate. The disparity between actual mean calcium substitution and the
theoretical need of 1.7 mmol/l is shown for two days (grey flashes). The total disparity is the sum of these daily differences, shown in grey for a
period of around 75 days. Broad arrows represent occurrence of spontaneous fractures. Computed tomographic imaging is indicated by grey
triangles with related number showing days after start of dialysis. Death occurred at day 254 of CVVHD.
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per day (around 2.9 g per day) has been observed [6].
In studies measuring bone mineral content (BMC)
and bone mineral density (BMD) by dual-energy X-ray
absorptiometry [7-9] a decrease in bone density of be-
tween 0.5% and 1.3% per month of immobilisation is
described [6]. However, no supportive data are available to
allow estimation of real calcium loss with respect to radio-
logical findings.
We therefore present an alternative means of estimating
calcium loss in immobilised critically ill patients requiring
dialysis. During CRRT and anticoagulation with citrate the
gap between theoretical and actual calcium substitution
represents the effective calcium loss [2], when intake and
intestinal loss are similar and anuria prevents renal loss.
In the current case a declining need for calcium supple-
mentation occurred after 4 weeks, in keeping with publi-
cations reporting significant bone demineralisation afterTable 1 Serum levels of parathyroid hormone (PTH), vitamin
PTH
Day of CVVHD at admission (−43) 152 18
Serum level (pg/ml) not done 237 28
Ca ionised (mmol/l) 1,18 1.13 1.0
Vitamin D: 25(O
Day of CVVHD at admission (−43) 32 15
Serum level (ng/ml) 30.2 9.3 9.6
Ca ionised (mmol/l) 1,18 1.01 1.1several weeks of immobilisation [10-13]. A cumulative
estimated calcium loss of 571 g was noted over the
254 day period of CVVHD. This loss correlates with
a semiquantative radiological measurement achieved
through sequential comparison of bone density of the
same skeletal region. As previous studies have re-
ported total skeletal calcium content at 1–1.5 kg [14]
the estimated calcium loss of 571 g reported here seems
plausible, albeit with neither spontaneous fractures nor
the semiquantative radiological assessment clinically prov-
ing this.
An average calcium loss of 2.2 g per day is however
somewhat higher than observed in most previous studies.
This could be accounted for by an accelerated bone loss
secondary to immunosuppression used after lung trans-
plantation i.e. calcineurin inhibitors and steroid therapy
[15], the observed androgen deficiency [16], or the excep-
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Figure 2 Sagittal plain computed tomographic imaging of the vertebral column over time. Computed tomographic imaging from four
different time points are shown. Region of interest within the thoracolumbar vertebral body is marked with a white square. Corresponding
Hounsfield Units (HU) at 3 years prior admission (242 HU), admission (238 HU), day 95 of CVVHD (52 HU), and day 226 of CVVHD (90 HU) are
labelled accordingly. Three years prior to admission bone mineral density (BMD) was within physiological limits with age-adjusted configuration
within normal limits for the thoracolumbar vertebrae. No significant change was found at admission. A significant decrease in BMD was noted at
4.5 months after admission (day 95 of CVVHD), with radiodensity decreasing to 52 HU preventing differentiation between the vertebral body edge
and the spinal canal. BMD increased to 90 HU after intervention.
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literature
Bisphosphonates were given to stop bone calcium loss
secondary to immobilisation, a practice first described in
the 1970s [4]. With the intention of increasing bone min-
eralisation, androgens were administered as proposed by
Gruenewald [16]. Together they resulted in a small in-
crease in need for calcium substitution during CVVHD
and anticoagulation with citrate, reflecting a reduction in
bone calcium loss. A concomitant increase in bone radio-
density was noted.
Long-term dialysis in literature
A total CVVHD duration of 254 days is exceptional com-
pared to reported prolonged CRRT-durations of >20 days
[2,17]. As such, the extent to which citrate anticoagulation
could promote bone demineralisation remains an import-
ant unanswered question. Heparin-based anticoagulation
in CRRT is often contraindicated in the critically ill. Fur-
thermore, an adequate dialysis dose effectively removes
calcium meaning hypercalcaemia remains ‘invisible’
when heparin-based anticoagulation is used, masking
a relative immobilisation hypercalcaemia [2]. Using
citrate for anticoagulation a further negative calcium
balance is maintained via continuous calcium losses
in the CRRT effluent [2]. However, the declining need
for substitution indicates indirectly the raising release
of calcium from the bone – this would remain invisible
using heparin for anticoagulation. Furthermore, long-
term treatment with heparin can also result in osteo-
porosis [18].Limitations
Due to the study design, markers with respect to bone
remodeling, bone formation, and bone resorption cannot
be provided. Dietary calcium intake was assumed to be
unchanged over time; however actual daily calcium intake
was not recorded in detail.
Conclusion
In immobilised patients receiving CRRT and regional
citrate anticoagulation, decreasing need for calcium sub-
stitution may help estimate the degree of bone loss over
time. Demineralisation and bone loss secondary to immo-
bilisation in critically ill patients are generally considered
less important with respect to disease severity and the
context of intensive care. We feel that the suggested
method would be helpful in bringing the problem of
immobilisation associated bone loss to the foreground.
Decreasing need for calcium substitution would act as
warning sign, triggering investigation of potential phy-
siological abnormalities e.g. androgen deficiency, and to
consider initiation of bone protective measures to counter
further bone loss. Such measures could prevent spontan-
eous fractures in long-term immobilised patients receiving
CRRT and regional citrate anticoagulation. In light of
this we recommend further evaluation of this proposed
method.
Consent
Written informed consent permitting publication of the
above case was obtained from the legal guardian of the
patient during the patient’s hospital stay.
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